Skip to main content
. 2007 Sep;14(9):616–624. doi: 10.1101/lm.597507

Figure 4.

Figure 4.

Post-acquisition scopolamine injections (immediately or 1 h after) in the prelimbic cortex. (A) Latency to make the correct response (±SEM) over the three first acquisition trials (Acq123), the two last acquisition trials (Acq45), the two first 24-h test trials (Retention), and the two last 24-h test trials (Relearning). The SCOP-Immed group demonstrates more latency to nose-poking than VEH-Immed and SCOP-1h both in retention and relearning. (B) Number of errors before making the correct response (±SEM) over the three first acquisition trials (Acq123), the two last acquisition trials (Acq45), the two first 24-h test trials (Retention), and the two last 24-h test trials (Relearning). The SCOP-Immed group commit more errors than the VEH-Immed group both in retention and relearning and also the SCOP-1h group in retention. The SCOP-Immed group significantly impaired performance from Acq45 to Retention, indicated by higher latencies and more errors. (***) P < 0.0001; (**) P ≤ 0.01; (*) P < 0.05.